DEF 14C: Cyclacel Pharmaceuticals to Increase Authorized Common Stock and Issue Series E Preferred Stock Following Majority Stockholder Approval

Cyclacel Pharmaceuticals is increasing its authorized common stock from 250,000,000 to 600,000,000 shares and issuing Series E Convertible Preferred Stock after receiving approval from a majority stockholder.

Summary

• Cyclacel Pharmaceuticals is notifying stockholders of actions approved by written consent of a majority stockholder on March 21, 2025.
• The company entered into a Securities Purchase Agreement with accredited investors to sell 1,000,000 shares of Series E Convertible Preferred Stock at $1.00 per share, raising $1 million.
• Each share of Series E Preferred Stock is convertible into 110 shares of common stock.
• The company is increasing the number of authorized shares of common stock from 250,000,000 to 600,000,000.
• The majority stockholder, holding approximately 93.87% of the voting power, approved the issuance of common stock upon conversion of the Series E Preferred Stock and the increase in authorized shares.
• The effective date of these actions will be no earlier than April 23, 2025.
• The company is not soliciting proxies and stockholders are not required to take any action.

Sentiment

Score: 4

Explanation: The document highlights the company's need for additional funding and the potential for dilution, which are negative factors. However, the successful private placement and increase in authorized shares provide some flexibility for the future.

Positives

• The $1 million raised from the Series E Preferred Stock issuance will provide capital for continued operations and clinical trials.
• The increase in authorized shares provides flexibility for future financing transactions, acquisitions, and equity awards.
• The company secured approval from a majority stockholder, streamlining the process and reducing costs compared to a proxy solicitation and special meeting.

Negatives

• The conversion of the Series E Preferred Stock will dilute the ownership of existing stockholders.
• The company has a history of losses and expects to incur losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may need to raise additional funds through public or private equity offerings, debt financings, or strategic alliances, which could further dilute existing stockholders or impose restrictive covenants.

Risks

• The company's reliance on additional funding to continue operations poses a risk if financing is not available on favorable terms or at all.
• The potential issuance of a significant number of shares upon conversion of the Series E Preferred Stock could substantially dilute existing stockholders' ownership.
• The increase in authorized shares could be used to discourage or prevent a takeover attempt, potentially limiting stockholders' ability to receive a premium for their shares.
• The company's dependence on the success of its sole product candidate, plogosertib, presents a significant risk.

Future Outlook

The company anticipates that it may issue additional authorized but unissued shares of common stock in the future in connection with financing transactions, partnerships, collaborations, equity incentive plans, strategic investments, and other corporate purposes.

Management Comments

• The board of directors believes that the Authorized Shares Increase is advisable, and in the Company's and its stockholders best interests, because it would provide the Company with sufficient shares of common stock to issue to the Investors in the Series E Preferred Stock and the flexibility to use the common stock for business and financial purposes and alternatives in structuring future transactions.
• The board of directors believes the Authorized Shares Increase will ensure the Company has sufficient authorized and unissued shares of common stock available to issue the full number of shares of common stock to issue to the Investors in the Series E Preferred Stock and enhance our flexibility in taking possible future actions, such as raising additional equity capital, issuing shares of common stock as consideration for acquisitions or licensing transactions, granting equity compensation awards or other corporate purposes.

Industry Context

Many clinical-stage biopharmaceutical companies face challenges in securing funding and managing cash flow, often relying on equity offerings and strategic alliances. Cyclacel's actions are consistent with this trend, as they seek to raise capital to fund ongoing clinical trials and maintain operations. The potential dilution of existing shareholders is a common trade-off in such situations.

Comparison to Industry Standards

• Many small-cap biopharmaceutical companies, such as Cyclacel, rely on private placements and convertible securities to raise capital.
• Increasing authorized shares is a common practice to provide flexibility for future financing and strategic transactions, similar to actions taken by companies like Novavax and Sorrento Therapeutics.
• The level of dilution resulting from the conversion of preferred stock is a key consideration for investors, and Cyclacel's potential dilution should be compared to similar transactions in the industry.

Stakeholder Impact

• Existing stockholders will experience dilution of their ownership percentage upon conversion of the Series E Preferred Stock.
• The company's ability to continue operations and develop its drug candidate depends on securing additional funding.
• Employees' job security and compensation may be affected by the company's financial performance.
• The company's ability to meet its obligations to suppliers and creditors depends on its financial stability.

Next Steps

• The board of directors will file a Certificate of Amendment effecting the Authorized Shares Increase at its sole discretion.
• The company will continue to pursue clinical trials for its drug candidate, plogosertib.
• The company may seek additional funding through various means, including public or private equity offerings, debt financings, or strategic alliances.

Key Dates

Keywords

Series E Preferred Stock, Authorized Shares Increase, Private Placement, Stockholder Approval, Common Stock, Cyclacel Pharmaceuticals, Dilution, Financing